Abstracts tagged "gout"

Abstract Number: 197 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone in Adults with Gout: A Phase 2a, Open-Label Study
Roy Fleischmann¹, Peter Winkle², Jesse Hall³, Shakti Valdez³, Sha Liu³, Xiaohong Yan³, Liz Hicks³ and Martha Hernandez-Illas⁴, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Anaheim Clinical Trials, Anaheim, CT, ³Ardea Biosciences, Inc., San Diego, CA, ⁴QPS MRA (Miami Clinical Research), Miami, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…
Abstract Number: 229 • 2016 ACR/ARHP Annual Meeting
Relationship Between Patient and Disease Factors and Severity of Gout in a Real-World Population
Michael Pillinger¹, Svetlana Krasnokutsky Samuels¹, Raymond Malamet², Bruce Schechter², Douglas CA Taylor³ and Robert Morlock⁴, ¹New York University, New York, NY, ²AstraZeneca, Gaithersburg, MD, ³Ironwood Pharmaceuticals, Cambridge, MA, ⁴Ardea Biosciences, Inc., San Diego, CA
Background/Purpose : Gout is the most prominent clinical manifestation of hyperuricemia, and is the most common cause of inflammatory arthritis. The symptoms of gout (eg,…
Abstract Number: 2298 • 2016 ACR/ARHP Annual Meeting
Incident Risk of Acute Gout Among Active Smokers: Data from Nationwide Inpatient Sample
Dilli Poudel¹, Paras Karmacharya¹ and Anthony Donato², ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Internal medicine, Reading Health System, WEST READING, PA
Background/Purpose: Smoking has been found to be negatively correlated with serum uric acid levels by virtue of reduced production and increased consumption of endogenous anti-oxidant…
Abstract Number: 204 • 2016 ACR/ARHP Annual Meeting
The Safety and Efficacy of Allopurinol Dose Escalation in People with Gout, a Randomised Controlled Trial
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: Allopurinol is the most widely used urate lowering therapy. Many patients on allopurinol fail to achieve target serum urate (SU), in part due to…
Abstract Number: 1013 • 2016 ACR/ARHP Annual Meeting
The Risk of Colchicine Associated Myopathy in Gout: Influence of Concomitant Use of Statin
Oh Chan Kwon¹, Byeongzu Ghang², Seokchan Hong³, Yong-Gil Kim⁴, Chang-Keun Lee³ and Bin Yoo⁴, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan Collage of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: To investigate the risk of concomitant use of statin on the development of myopathy in gout patients who received colchicine. Methods: We included patients…
Abstract Number: 2299 • 2016 ACR/ARHP Annual Meeting
Predictors of Mortality in People with Recent Onset of Gout: A Prospective Observational Study
Zoe Vincent¹, Gregory Gamble², Meaghan House², Julie Knight¹, Anne Horne², William J. Taylor³ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Wellington, New Zealand
Background/Purpose: Many studies have reported that gout is associated with increased risk of cardiovascular events and mortality. However, information regarding gout disease severity is limited…
Abstract Number: 206 • 2016 ACR/ARHP Annual Meeting
Renal Safety of Lesinurad: A Pooled Analysis of Phase III and Extension Studies
Robert Terkeltaub¹, Raymond Malamet², Kathleen Bos², Jingyi Li², David Goldfarb³, Michael Pillinger⁴, Diana Jalal⁵, Jia Hu⁶ and Kenneth Saag⁷, ¹Rheumatology, VA Medical Center, San Diego, CA, ²AstraZeneca Pharmaceuticals, Wilmington, DE, ³New York University School of Medicine, New York, NY, USA, New York, NY, ⁴Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ⁵University of Colorado Anschutz Medical Center, Aurora, CO, USA, Aurora, CO, ⁶Ardea Biosciences, Inc., San Diego, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL
Background/Purpose: Lesinurad is a selective uric acid reabsorption inhibitor approved in the United States and European Union at 200 mg daily dose in combination with…
Abstract Number: 1099 • 2016 ACR/ARHP Annual Meeting
Synovial Exosomes Induce Osteoclast Differentiation in Rheumatoid arthritis
Ji Eun Song¹, Ji Hye Shin¹, Ki Won Moon², Se Hui Shon¹, Ji Soo Park³, Eun Bong Lee³, Yeong Wook Song^1,3 and Eun Young Lee³, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea, Seoul, Korea, The Republic of, ²Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Republic of Korea, Chuncheon, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, The Republic of
Background/Purpose: Exosomes are small membrane vesicles (40-150 nm) of endocytic origin secreted by many types of cells and engage in cell-to-cell communication by transferring proteins,…
Abstract Number: 2300 • 2016 ACR/ARHP Annual Meeting
Tophaceous Gout and the Risk of Mortality: A General Population-Based Study
Hyon K. Choi¹, Leo Lu², Sharan K. Rai^3,4 and Yuqing Zhang⁵, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA
Tophaceous Gout and the Risk of Mortality: A General Population-Based Study Background/Purpose: A recent study based on data from a gout specialty clinic (N=706) found…
Abstract Number: 207 • 2016 ACR/ARHP Annual Meeting
Integrated Safety of Lesinurad, a Novel Uric Acid Reabsorption Inhibitor for the Treatment of Gout
Michael A. Becker¹, Robert T. Keenan², Puja Khanna³, Raymond Malamet⁴, Kathleen Bos⁴, Jingyi Li⁴, Jia Hu⁵ and William White⁶, ¹University of Chicago, Chicago, IL, ²Rheumatology, Duke University, Durham, NC, ³Rheumatology, University of Michigan, Ann Arbor, MI, ⁴AstraZeneca Pharmaceuticals, Wilmington, DE, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶University of Connecticut School of Medicine, Farmington, CT
Background/Purpose: Lesinurad is a selective uric acid reabsorption inhibitor recently approved at 200 mg daily in combination with a xanthine oxidase inhibitor (XOI) for treatment…
Abstract Number: 1242 • 2016 ACR/ARHP Annual Meeting
Rate of Hospitalization for Heart Failure Is Lower in Patients with Controlled Gout Versus Uncontrolled Gout
Robert Morlock¹, Pierre Chevalier² and Alyssa B Klein³, ¹Ardea Biosciences, Inc., San Diego, CA, ²IMS Health, New York, NY, ³AstraZeneca, Gaithersburg, MD
Background/Purpose: Hyperuricemia is associated with worsened outcomes in heart failure (HF) patients. However, little is known regarding the association between gout and HF itself. This…
Abstract Number: 2303 • 2016 ACR/ARHP Annual Meeting
Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada from 2000-2011
Sharan K. Rai^1,2, J. Antonio Avina-Zubieta^2,3, Natalie McCormick^2,4, Mary A. De Vera^2,5, Diane Lacaille^2,6, Eric C. Sayre² and Hyon K. Choi^7,8, ¹Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁶Medicine, University of British Columbia, Vancouver, BC, Canada, ⁷Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁸Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Gout and rheumatoid arthritis (RA) are the two most common forms of inflammatory arthritis worldwide. As hospitalizations for both conditions lead to substantial health…
Abstract Number: 223 • 2015 ACR/ARHP Annual Meeting
Increased Platelet Reactivity in Gout: A Potential Mechanism for Adverse Cardiovascular Events
Richard Conway¹, Claire-Louise Murphy², Anne Madigan², Patricia Kavanagh², Liz Geraghty², Laura Helbert², Kelly Stephens³, John J. Carey⁴, Eimear Dunne⁵, Dermot Kenny⁵ and Geraldine M. McCarthy⁶, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 2, Ireland, ²Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³Mater Misericordiae University Hospital, Clinical Research Center, Dublin, Ireland, ⁴Rheumatology, Galway University Hospitals, Galway, Ireland, ⁵Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ⁶University College Dublin, Dublin, Ireland
Background/Purpose: Patients with inflammatory arthritis, including gout, have an increased risk of cardiovascular events and mortality. Increased platelet reactivity is a risk marker for cardiovascular…
Abstract Number: 2099 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Clinically-Defined Gout Identifies Multiple Risk Loci: A Clue for Future Companion Diagnostics of Gout
Hirotaka Matsuo¹, Ken Yamamoto², Hirofumi Nakaoka³, Akiyoshi Nakayama¹, Masayuki Sakiyama¹, Atsushi Takahashi^4,5, Takahiro Nakamura⁶, Yusuke Kawamura¹, Nobuyuki Hamajima⁷, Ituro Inoue⁸, Michiaki Kubo⁴, Kimiyoshi Ichida⁹, Hiroshi Ooyama¹⁰, Toru Shimizu¹¹ and Nariyoshi Shinomiya¹, ¹Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ²Department of Medical Chemistry, Kurume University School of Medicine, Kurume, Japan, ³Division of Human Genetics, Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan, ⁴Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁵Research Center, National Cerebral and Cardiovascular Center, Suita, Japan, ⁶National Defense Medical College, Laboratory for Mathematics, Tokorozawa, Japan, ⁷Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁸Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan, ⁹Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan, ¹⁰Ryougoku East Gate Clinic, Tokyo, Japan, ¹¹Midorigaoka Hospital, Takatsuki, Japan
Background/Purpose: Gout, caused by hyperuricaemia, is a multifactorial disease. Recently, genome-wide association studies (GWASs) of gout have been reported; however, they included self-reported gout cases.…
Abstract Number: 2352 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety in Patients with Tophaceous Gout Receiving Lesinurad and Febuxostat Combination Therapy: Interim Analysis of an Extension Study
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Scott Adler⁶, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁵, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: In the randomized, double-blind, placebo-controlled, Phase III CRYSTAL trial, more patients taking lesinurad 200 mg (LESU200) or 400 mg (LESU400), in combination with febuxostat…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].